X4 Pharmaceuticals Inc
NASDAQ:XFOR
Intrinsic Value
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of XFOR.
X4 Pharmaceuticals Inc's market capitalization is 211m USD.
XFOR stock price is 1.26 USD.
XFOR.
XFOR. Open DCF Valuation
XFOR. Open Relative Valuation
XFOR has upside potential of 187% compared to the average analyst price target.
Open Wall St Estimates
XFOR's D/E (Debt to Equity) is equal to 1.07.
XFOR's long-term assets (147m USD) exceed its long-term liabilties (96m USD).
XFOR's ROE (Return on Equity) has significantly decreased in the last 3 years from -69% to -162%, and is approaching profitability.
XFOR's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -167% to -429%, and is approaching profitability.
XFOR has negative Operating Income for the last twelve months.
XFOR has negative Net Income for the last twelve months.
XFOR's ROE (Return on Equity) for the past 12 months is negative and is equal to -162%.
XFOR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -429%.
XFOR has negative Net Debt. This means that the company has more cash and short-term investments (114m USD) than debt (55m USD).
XFOR has negative Free Cash Flow for the last twelve months.
XFOR has negative three-year average ROE (Return on Equity): -143%. The company is not efficient at transforming stockholders' equity into net income.
XFOR has negative three-year average ROIC (Return on Invested Capital): -262%. The company is not efficient at using invested capital to generate operating income.
XFOR's short-term assets (122m USD) exceed its short-term liabilties (23m USD).
XFOR's Altman Z-Score is very low and is equal to -6.2.
XFOR doesn't generate enough operating income (-108m USD) to safely cover interest payments on its debt (5m USD).
Fundamental Analysis
X4 Pharmaceuticals Inc
Balance Sheet Decomposition
X4 Pharmaceuticals Inc
| Current Assets | 122.1m |
| Cash & Short-Term Investments | 114.2m |
| Receivables | 562k |
| Other Current Assets | 7.3m |
| Non-Current Assets | 25.2m |
| PP&E | 6.4m |
| Intangibles | 17.4m |
| Other Non-Current Assets | 1.4m |
| Current Liabilities | 22.9m |
| Accounts Payable | 8.9m |
| Accrued Liabilities | 13.9m |
| Non-Current Liabilities | 73.3m |
| Long-Term Debt | 54.6m |
| Other Non-Current Liabilities | 18.7m |
Earnings Waterfall
X4 Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-107.5m
USD
|
|
Operating Income
|
-107.5m
USD
|
|
Other Expenses
|
6.4m
USD
|
|
Net Income
|
-101.2m
USD
|
Free Cash Flow Analysis
X4 Pharmaceuticals Inc
What is Free Cash Flow?
XFOR Profitability Score
Profitability Due Diligence
X4 Pharmaceuticals Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
X4 Pharmaceuticals Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
XFOR Solvency Score
Solvency Due Diligence
X4 Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
X4 Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XFOR Price Targets Summary
X4 Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
XFOR
is 3.62 USD
with a low forecast of 1.01 USD and a high forecast of 5.25 USD.
Ownership
XFOR Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
XFOR Price
X4 Pharmaceuticals Inc
| Average Annual Return | -48.45% |
| Standard Deviation of Annual Returns | 16.01% |
| Max Drawdown | -97% |
| Market Capitalization | 211m USD |
| Shares Outstanding | 167 940 000 |
| Percentage of Shares Shorted | 7.36% |
Company Profile
X4 Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company is headquartered in Boston, Massachusetts and currently employs 83 full-time employees. The company went IPO on 2017-11-16. The firm is focused on the research, development and commercialization of therapeutics for the treatment of rare diseases with an initial focus on the treatment of people with immune system dysfunction. Its lead product candidate, mavorixafor, is a small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Its mavorixafor demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells (WBCs), which provides therapeutic benefit across a variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Its mavorixafor is in a global Phase III clinical trial for the treatment of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome, a rare, inherited PID caused by genetic mutations in the CXCR4 receptor gene. Its product candidates include X4P-001, X4P-002 and X4P-003.
You don't have any saved screeners yet
